Abstract
The decision to offer adjuvant chemotherapy after primary resection for non-metastatic colorectal cancer (CRC) is principally guided by histopathologic parameters. However, this approach lacks precision with many patients potentially receiving unnecessary treatment. For example, only about 1 in 20 patients with stage II colon cancer will benefit from adjuvant chemotherapy (1). In large part, this is due to the lack of prognostic biomarkers to precisely stratify patient risk and to guide a personalised approach to treatment. Additionally, for the past 15 years there has been no progress in developing more effective adjuvant therapy beyond oxaliplatin and fluoropyrimidine (2-6).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
